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ABSTRACT OF THESIS 
DISCOVERY OF 
SELECTIVE PROBES TARGETING RNA POLYMERASE I 
RNA Polymerase I (RNA Pol I) is a “factory” that orchestrate the transcription of 
ribosomal RNA for constructing ribosomes as a primary workshop for protein translation 
to sustain cell growth. Deregulation of RNA Pol I often cause uncontrolled cell 
proliferation leading to cancer. Efficient and reliable methods are needed for the 
identification of selective inhibitors of RNA Pol I.  Yeast (Saccharomyces cerevisiae) is 
eukaryotic and represent a valuable model system to study RNA Pol I, especially with the 
availability of the X-ray crystal structure of the yeast homologue of RNA Pol I, offering 
structural basis to selectively target this transcriptional machinery. Herein, we developed 
a cell-based screening strategy by establishing a stable yeast cell line with stably 
integrated human RNA Pol I promoter and ribosomal DNA. The model system was 
validated using the well-known RNA Pol I inhibitor, CX-5461 by measuring the 
transcribed human rRNA as a readout. Virtual screening coupled with compound library 
screening using this cell line enabled the identification of a new candidate inhibitor of 
RNA Pol I, cerivastatin sodium. Furthermore, we used growth assays and gel 
electrophoresis, to biologically evaluate the hit. The result implicates cerivastatin sodium 
as a selective RNA Pol I inhibitor worthy of further development with potential as 
targeted anticancer therapeutic. 
KEYWORDS: RNR Polymerase I, Yeast, Cerivastatin Sodium, CX5461, YIPlac211-
TG1, YBR140C. 
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CHAPTER 1.  INTRODUCTION 
1.1 Background Knowledge of RNA Polymerase I 
1.1.1 Myc Gene Family and RNA Polymerases 
The Myc gene family includes a couple of proto-oncogenes coding for 
transcription factors. Overexpression of proto-oncogenetic Myc genes was determined to 
cause cancer development in studies of diverse organs including intestine by Kim et al 
(2018)1 , testicular by Corbineau et al (2017)2, liver by Zhao el al (2016)3, etc. Study 
using multiple cell strains by Ji et al (2011)4 has shown that activated MYC genes induce 
cell mass accumulation and cell proliferation. This stimulation of cell growth heavily 
depends on production of ribosome as well as transcription and maturation of multiple 
types of RNAs, both of which are intensely supported by the activities of RNA 
polymerases. 
In eukaryotes, RNA Pol II is a nucleoplasm polymerase that produces mRNAs for 
supplying cells growth with proteins. Transcription activities of RNA Pol III yield 5s 
rRNA, tRNA and small sized non-coding RNAs that involve with metabolism, which 
had been studied by Roeder et al (1969)5. In comparison, eukaryotic RNA Pol I is 
localized in nucleoli and its specific DNA template to work on is ribosomal DNA. 
Transcription of rDNA by RNA Pol I yields 47S pre-rRNA, which is subsequently 
processed into 18 S, 5.8 S and 28 S rRNAs5 6 as depicted in (Figure 1.1). These rRNAs 
are important building materials for ribosome, which is the organelle for synthesizing 
new proteins7. Analysis by Fernandez-Tornero et al (2013)8 showed that RNA Pol I is a 
multi-subunit enzyme that had 14 subunits. In comparison, RNA Pol II possess 10 
subunits9.  
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Figure 1.1  Structure of a Single Repeat of Yeast Ribosomal DNA 
 
 
1.1.2 Structure and Functions of rDNA as RNA Pol I’s Template 
As the template for RNA Pol I, eukaryotic rDNA of both human and yeast have 
multiple copies of rDNA sequences. Yeast genome contains 150 to 200 repeats of rDNA 
within chromosome XII10 whereas human beings have about 400 copies of rDNA repeats 
that are distributed in five chromosomes11.  
As one copy of the multiple repeats, a typical rDNA for eukaryotes includes three 
significant components: proximal promoter12, enhancers13 and space-promoters and 
terminators14. Proximal promoter is needed for sequence-specific initiation of rDNA 
transcription12. Experiments of point mutation and sequence deletion within the promoter 
regions of the mouse rDNA at different distances from the transcription starting point of 
the rDNA suggested it was proximal promoter (Figure 1.2) that controlled the initiation 
of rDNA transcription12 15. 
 
Figure 1.2 Structure of a Single Repeat of Yeast Ribosomal DNA (rDNA) 
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1.1.3 Structure of RNA Pol I for Yeast and Human RNA Pol I 
RNA Pol I of Yeast (Saccharomyces cerevisiae) is a multi-subunit enzyme and 
its crystallized structure reveals 14 subunits that are originally named as A190/ 
RPA190, A135/ RPA135, AC40, A14, ABC27, ABC23, A43, ABC14.5, A12.2, ABC5, 
RPA19/ AC19, ABC4, A49, A34.5 16 17. A 3D structure of Yeast RNA Pol I in complex 
with RRN3 at a resolution at 4.8 angstrom has been published by Russell and Zomerdijk 
(2006)17 as shown by (Figure 1.3). The file documenting this protein complex is 
deposited in Protein Data Bank with the referable code of 5g5l, of which the subunites 
were depicted in (Figure 1. 4)17. The subunits collaborate in sustaining the structure or 
functioning for specific processes of rDNA transcription. Of all these subunits, the RNA 
Pol I subunits A190, A135 and A12.2 are also referred to as RPA194, RPA135 and 
RPA12 and were determined to constitute the catalytically active center including the 
DNA binding cleft8. A serial combination of protein expression using plasmids 
containing cDNA, chromatographic extraction using His-tag, using resolution by SDS-
PAGE and interaction assay reported using autoradiography done by Peyroche et al 
(2002)18 had revealed a strong interaction between RNA Pol I subunit A43 and A14. 
Such a interaction was strong enough to hold this two subunits within a complex19. 
 
 
Figure 1.3 Yeast RNA Pol I with and without Contact Presence of RRN3  
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Figure 1.4 Structure of Yeast RNA Pol I 
 
 
 The 3D structural images of RNA Pol I obtained from cryo EM by Tafur et al 
(2016)20 provide direct evidence as well as structural depiction of A43 as a mediator that 
recruit two RNA Pol I enzymes to form a dimerization. Their data also described a bridge 
helix (BH) formed by Amino Acid Residues 1012-1016 of subunit RPA190. Their data 
described how BH either contract or extend in order to close or open the DNA binding 
cleft. Ultimately their results clarified and how structural changes within RPA190 could 
switching RNA Pol I from one dynamic structure within the opening complex to another 
within the elongation complex during the transcription cycle. 
1.2 RNA Polymerase I as a Promising Anti-Cancer Target 
 The characteristic fast proliferation of cancer cells strongly replies a much higher 
capacity of cellular protein synthesis. To compensate for protein errors and loss cancer 
cells are pressured into increased protein synthesis at higher levels21. Such a reliance for 
fast protein synthesis in turn heavily depends on construction of new ribosomes, of which 
rRNA synthesized by RNA Pol I is a significant building material. Prior research also 
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showed that for the cellular levels of ribosome the accessibility of rRNA is a significant 
determinant 22. 
Moreover, the RNA Pol I transcription constitutes up to 60 % of all cellular 
transcription among the three RNA polymerases, and rRNAs make up about 80 % of the 
RNA content of living cells23. Therefore, RNA Pol I is crucial in controlling cell growth 
and its misregulation is associated with aberrant cell growth and thus increased risk of 
cancer. Study by Bywater et al (2012)24 reported the direct cellular evidence for enhanced 
ribosomal DNA transcription levels by increased RNA Pol I activity as a cause of cancer 
progression. The same study also lend evidence that selective inhibition of RNA Pol I 
could contribute to apoptosis of specific human malignant cells like lymphoma cells and 
thus is a promising therapy against cancer. Inhibitors to the rDNA transcription function 
of RNA Pol I could probably suppress growth of cancer cells and thus be used as targeted 
anti-cancer drugs25. 
1.3 Challenges in Obtaining Selective Inhibitors to RNA Pol I 
RNA Pol I remains an important target for anti-cancer therapy that screening and 
designing specific inhibitors to this enzyme is valuable. However, this goal is challenging 
for a couple of reasons.  
First, the high structural similarity shared by all three RNA polymerases might 
make it difficult to achieve small molecule selectivity. Structural comparison done by 
Cramer et al of all three RNA polymerases reveals highly conserved active site26. 
Identified RNA Pol I inhibitors screened based on blockage of substrate (DNA) access to 
the catalytic active site, opens the possibility for such an inhibitor to simultaneously 
inhibit either or both of the other counterpart polymerases.  
The second challenge is the lack of high-throughput assay methods to quantify 
rRNA, which is the product of RNA Pol I catalysis. Multiple challenges therefore exist in 
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monitoring rRNAs transcribed by RNA Pol I following treatment of compound libraries. 
A major limitation is the short half-life of rRNA, which is ~20 and 30 minutes and 
sensitive to degradation27. Therefore, resultant RNA extracts must be handled strictly in 
RNase and nucleotide free buffers during their extraction and storage. Were the 
transcription quantified directly using reverse transcription qRT-PCR assay, the operation 
would be laborious and require stringent operation conditions in order to generate 
accurate and precise data. The third reason is that there has not been a fully elucidated x-
ray crystal structure of Human RNA Pol I. Therefore, it requires designing a persuasive 
protein model to identify candidate compounds targeting human RNA Pol I. 
Moreover, it is important to take into account selective RNA Pol I probes or 
inhibitors that are safe to normal functions of healthy cells. Some effective anticancer 
drugs, targeting RNA Pol I may also have unpleasant side effects leading to high cellular 
toxicity28 as exemplified in Actinomycin D in (Figure 1.5). This well-known anticancer 
drug lacks selectivity against RNA Pol I and has been shown to inhibit RNA Pol II27. 
This drug, therefore, might be disadvantageous to normal cellular function like protein 
synthesis. More innovative screening approaches to access selective RNA Pol I inhibitors 
are needed. 
 
 
 
Figure 1.5  Structure of Actinomycin D 
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1.4 Unique Structural Hints of RNA Pol I for Inhibitor Design 
To overcome the outlined drawbacks (vide supra) that limit rational design of 
potent specific RNA Pol I inhibitors, novel concepts with important compatible screening 
methods are required. Identification of such inhibitors require comprehensive knowledge 
of the precise structures of RNA Pol I as well as other macro biomolecules that closely 
interact with the RNA Pol I in the whole process of transcription and its regulation. 
 
1.4.1 Regulatory Factors of RNA Pol I for Yeast and Human 
For human RNA Pol I there are two important factors, Upstream Binding 
Factor (UBF) and Selective Factor 1 (SL1) that bind the promoter region of human 
rDNA, recruit the other molecules that participate in the formation of transcription 
complex (Figure 1. 6). SL1 interacts with promoter DNA in a highly sequence-specific 
manner as illustrated (Figure 1. 6) by the sequence-specific nature of rDNA onto 
sequences from upstream promoter element and core promoter element during initiation 
of transcription 29 30 31. The counterpart factor of SL1 in yeast is TIF-1B; the two factors 
differ in that binding of SL1 to human rDNA promoter requires UBF whereas the TIF-1B 
binds with yeast rDNA promoter in the absence of UBF 29. These structural distinctions 
can be further exploited to obtain RNA Pol I specific small molecule inhibitors. 
Another important regulatory factor for RNA Pol I is RPA53. Recent research 
showed this acetylation as well as de-acetylation of a specific lysine residue on this factor 
could increase or decrease the transcription activity of rDNA32. 
1.4.2 Protein Factors Having Direct Contact with RNA Pol I  
There are a couple of protein factors that regulate the transcription activity of 
RNA via direct contact. One of these transcription factors, Rrn3 was identified as a 
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unique binding factor33 that directly interacted with Yeast RNA Pol I to form an initiation 
complex. Their investigation also showed Rrn3 would specially recognize sequences of 
Yeast rDNA and recruit RNA Pol I to that promoter region. This process is noticeable in 
being independent of the rDNA sequence. Rrn3 ultimately recruits RNA Pol I to the 
specific rDNA promoter regions 34. Later investigations35 showed that Rrn3 binds RNA 
Pol I as a monomer. Characterization of the interfaces between RNA Pol I and Rrn3 
would probably provide with valuable information for designing RNA Pol I inhibitors 
based on destabilization of the complex formed by these two biomolecules. The surface 
image of average position depicted by the immunolocalization experiment18 provided 
direct evidence for the formation of a complex of A43 from RNA Pol I and Rrn3 as 
depicted in (Figure 1.6). 
 
 
Figure 1.6  Surface Image Model of Yeast RNA Pol I 
 
Investigation by Blattner et al (2011) 35 showed a serine (S154) patch on the 
interface between Rrn3 and RNA Pol I during the formation of transcription complex. 
Once this serine (S154) was phosphorylated, binding between Rrn3 and RNA Pol I would 
be suppressed. This blockage would in turn inhibit RNA Pol I’s transcription activity as 
well as cell growth 35. This provides with significant hint for inhibitor design. Because 
the serine patch on Rrn3 fits in the site formed between two RNA Pol I subunits: AC 
40/19 and A14/43 while binding takes place, screening compounds that have high affinity 
to this binding site may be possible. 
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 Experimentally virtual screening can be done using the known structural data of 
RNA Pol I and its specific transcription factors. Molecular docking using programs 
including Autodock and SYBYL-X can be carried out for the structural data of RNA Pol 
I with the virtual structural files of compound candidates.  
Our project hypothesizes that compounds that can destabilize the complex formed 
between the apozyme of Pol I and Rrn3 can be a potential selective inhibitor to RNA Pol 
I function and thus be used as anti-cancer drugs. 
1.5 Prior Researches about Selective Inhibitors to RNA Pol I  
Bio-models containing the source of RNA Pol I are indispensable for assaying 
this enzyme’s activity. Prior researches had adopted diverse systems such as diverse 
cancer cell lines, cellular extract and purified RNA Polymerases as source of RNA Pol I 
to design activity assays. For the activity assays the design for quantifying the enzyme 
activity is a major concern for assessing the inhibitory potency of the ligands to be tested. 
Once a potential inhibitor is screened, a selectivity test is necessary for assessing its value 
as a drug candidate. Usually a Pol I inhibitor is expected not to inhibit Pol II at the dose 
with therapeutic efficacy in order not to disturb the desired function of RNA Pol II in 
transcription of the house keeping genes, which would yield the mRNA for the functional 
proteins like enzymes. 
 
1.5.1 Prior Bio-Models Assaying RNA Pol I 
Screening the experimental hit of selective inhibitors to RNA Pol I requires 
efficient design of a bio-system containing RNA Pol I as well as other protein factors, as 
well as the template DNA containing the rDNA and promoter. These constitute the 
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molecular basis for an assay to quantify the transcription activity of RNA Pol I. The cell 
system assaying RNA Pol I were usually human cancer cells because their levels of RNA 
Pol I transcription activities were high. Prior studies used diverse lines with advantages 
that were desirable for anti-cancer drugs’ development. One of such cell lines was the 
NCI60 cell lines 36 37. Another cell line was HeLa S3 which could form colonies much 
more easily at relatively lower concentrations of nutrient supply such as human serum 
and formed bigger and more stable colonies than other strains of Hela cells38. Cell lines 
from Eμ-Myc B These cell lines were selected and cultured for the purpose of screening  
anti-cancer drugs via inhibition to the cell’s proliferation. 
In other bio-model of RNA Pol I study used lines of lymphoma cells like murine 
Eμ-Myc-lymphoma cells and Eμ-Myc-B cells 39 because these cell lines demonstrated 
high levels of protein factors for RNA Pol I’s transcription high levels of rDNA 
transcription. Therefore, these cell lines could generate more evident signals of 
proliferation inhibition with presence of inhibitors as anticancer drugs like CX-5461 
(Figure 1.7) and provide with a desirable comparison with RNA Pol I inhibitors to be 
studied 24. In the same research, a comparison in dose dependent tests between malignant 
B cells and the wild type B cells revealed that CX54-61 also selectively suppress the B-
lymphoma cells that were cancerous target 24. 
 
 
Figure 1.7  Structure of CX-5461 
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  HepG2 cells had also been used for building an rDNA transcription assay by 
Ghoshal et al (2004) 11 with the firefly luciferase as the reporter enzyme for RNA Pol I 
transcription. This cell line was probably more desirable as the host for RNA Pol I driven 
transcription that was assayed using reporter enzymes since the data showed HepG2 cell 
had higher luciferase activity driven by RNA Pol I transcription than Hela cells. 
There are many published methods that reported bio-models assaying RNA Pol I 
activity using cancer cell extracts instead of whole cancer cells. Kurl et al (1984) 40 had 
successfully transcribed rat rDNA using rat mammary adenocarcinoma ascites cells as 
the start to make such a cell-free in vitro assay. Their work obtained two 
chromatographic fractions with DEAE-Sephadex column and tandem fraction combining 
both DEAE-Sephadex column and heparin-Sepharose column from rat cells that could 
yield an over 90 percent of RNA Pol I transcription activity. Their work showed that a 
cellular extract could concentrate RNA Pol I through chromatographic fraction with 
DEAE-Sephadex column followed by a second round of fraction through heparin-
Sepharose column chromatography. Furthermore, the following fractionation using 
heparin-Sepharose column chromatography turned out to increase the extract’s RNA Pol 
I transcription activity. Interestingly, chromatographic phosphocellulose was suggested 
not to be used during the early phase of fractionation in order to prevent from the loss of 
activity in rDNA transcription. Except for a source of RNA Polymerase I, another 
essential component for the bio-system assaying rDNA transcription was a template 
DNA containing rDNA together with an adjacent promoter. Such a template could be the 
rDNA plus promoter within a whole cell’s intact genome. It also could be a DNA 
sequence containing the rDNA of interest plus rDNA promoter that were cut out directly 
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from a creature’s genome. It could also be a recombined plasmid containing the rDNA 
with promoter. Ghoshal et al (2004)11 had constructed an rDNA template as a plasmid 
named as pHrD-IERS-Luc in which luciferase reporter was in a tandem followed by an 
IRES-human rDNA sequence. This project discovered that methylation of the nucleotides 
constituting the rDNA promoter would weaken the transcription of rDNA catalyzed by 
RNA Pol I.   
Prior studies had developed multiple assays quantifying RNA Pol I activity. 
Direct quantification had been done reverse transcription qRT-PCR assay using the 45S 
rRNA as the RNA template and nuclear extract from HeLa S3 cells as the RNA Pol I 
source in one project investigating CX-4561 as RNA Pol I inhibitor 41. Indirectly 
quantifying the rDNA transcription activity of RNA Pol I by activity of a reporter 
enzyme had been an existing strategy. For example, Ghoshal et al (2004)11 had designed 
an in vitro assay to quantify Human rDNA transcription activities using firefly luciferase 
as illustrated in (Figure. 1.8). 
 
 
Figure 1.8  Construction of pHrD-IRES-Luc Plasmid 
 
 
1.5.2 Studies of Interaction between RNA Pol I and Inhibitors 
Another concern of RNA Pol I study is the molecular mechanism via which each 
inhibitor act on RNA Pol I. Several inhibitors were verified to work exclusively by 
disturbing the formation of transcription complex and do not directly degrade the cancer 
cells. For instance, research with a compound called CX-5461 implicated it was a 
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potential anticancer drug candidate against development of diverse cancer tissues by 
inducing cancer cells’ autophagy, senescence as well as by inhibiting the transcription 
activity of RNA Pol I via blockage against the formation of transcription initiation 
complex 41 24. It is also noticeable that CX-5461 was concluded as acting in an 
independent of P53 pathway and was able to induce apoptosis41. Similarly, another drug 
called 9-Hydroxyellipticine was shown as a disturber of the interaction between Human 
rDNA promoter and SL1 during the formation of preinitiation complex42. Research by 
Colis et al (2014) 25 had investigated pyridoquinazolinecarboxamides and its 
derivatives as RNA Pol I inhibitors. BMH-21 was also found to be a potent RNA Pol I 
inhibitor that could block the RNA Pol I holocomplex from binding to rDNA and thus 
inhibit the RNA Pol I’s transcription activity43. In the same project a series of BMH-21 
derivatives were synthesized and tested in rDNA transcription activity assay. A 
comparison showed that the BMH-21 compound series all intercalated with rDNA but 
only 12H-benzo[g] pyrido [2,1-b] quinazoline-4-carboxamide, N-[2 (dimethylamino) 
ethyl]-12-oxo, which they named as BMH-21(2). Their study used NCI60 human tumor 
cell line 37 and successfully demonstrated that BMH-21 competed with RNA Pol I for the 
GC region binding site of the human rDNA instead of contacting with the active site on 
the surface of RNA Pol I. Moreover, the same research found BMH-21 could degrade 
RBP194 subunit of RNA Pol I 43 and thus block the formation of initiation complex in an 
alternative strategy as compared to CX-5461. 
1.5.3 Selectivity of RNA Pol I Inhibitors to Growth of Cancer Cells  
Nucleolin as another RNA Pol I inhibitor, was studied in both inhibitory potency 
and selectivity by Roger et al. Their work showed nucleotin could suppress transcription 
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of rDNA by RNA Polymerase I whereas function of RNA Pol II and Pol III remained 
unaffected. Nucleolin was concluded to inhibit RNA Pol I via direct disturbance of Pol 
I’s interaction with rDNA and depended specially on the sequence of promoter instead of 
pre rDNA44. Andrews et at (2013)42 had conducted study that focused on finding 
selective RNA Pol I inhibitors from old drugs using a couple of human cell strains. They 
used three transcription assays targeting rDNA for RNA Pol I, a group of housekeeping 
genes targeting RNA Pol II and 5s plus 7s rDNA targeting RNA Pol III. These strict 
screening identified a highly efficient and selective RNA Pol I inhibitor from the 
ellipticine family: 9-Hydroxyellipticine (9HE). Impressively they had also conducted a 
series of other assays with anticancer drug targets including p53, ATM/ATR, and Top2 
and found that none of these were affected by 9HE. 
1.6 Basis of Using Yeast RNA Pol I to Anticancer Drugs’ Design  
Yeast (Saccharomyces cerevisiae) has become a model for investigating complex 
molecular genetic processes like transcription of eukaryotes that are multicellular because 
it is easy to process 45 and the conservation in protein functions between yeast and other 
eukaryote like human beings 46 45 47. Yeast RNA Pol I is also the only eukaryote of which 
the RNA Pol I’s structure has been fully characterized. 
For Saccharomyces cerevisiae (Yeast) RNA Pol I exclusively works on 35s 
rDNA48. Sequence alignments done using a couple mammalian RNA Pol I subunits 
(cloned using their cDNAs) with their counterpart subunits from in yeast RNA Pol I 
indicated high homology49. Moreover, experiments also showed four subunits were 
functionally interchangeable between human and yeast. Therefore, in our project a 
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hypothesis has been made that yeast RNA Pol I might also be able to be recruited to 
human rDNA’s promoter within the yeast cell and thus transcribe human rDNA. 
The goal of project, as shown in (Figure 1. 9), is to build a new model that is able 
to elucidate RNA Pol I inhibitor with structural explanation based on an elucidated 
eukaryotic RNA Pol I structure as well as a rDNA template plus promoter, both of which 
are from Human genome.  This model uses yeast cell as the source of RNA Pol I and 
other necessary transcription factors. The template for rDNA and promoter is from 
human genome sequence. In this project, human ribosomal DNA (rDNA) plus the 
promoter was cut out and inserted in yeast integrative plasmid of YIPlac211-TG1 as a 
generous gift from the lab of Brian C. Rymond. This plasmid contains a sequence of 
URA3 gene50 encoding orotidine-5'-phosphate decarboxylase that is an inducing 
enzyme for synthesis of pyrimidine ribonucleotides de novo51. Human rDNA plus 
promoter is supposed to be integrated within the yeast integrative plasmid containing 
URA3 gene, of which the expression enables the survival of originally URA3 deficient 
yeast cells to survive and grow on the medium plate with deficiency in uracil. Therefore, 
the yeast cells that had successfully incorporated the recombined plasmid containing 
human rDNA with promoter will be selected. The YBR140C strain of yeast with 
deficiency in URA3 gene (also a gift from the lab of Brian C. Rymond) was used as the 
host for selecting the cells with targeted insertion mutagenesis of human rDNA plus 
promoter following the protocol by Klinner et al (2004)52. Thus, a new strain of yeast 
was created with human rDNA within its genome.  
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Figure 1.9 Construction of Bio-Model for Assaying Dose Responses of 
Yeast RNA Pol I to RNA Pol I Inhibitors 
 
Considering the high sensitivity of rDNA to degradation, one strategy of this 
project is to combine cellular assay of transformed yeast with Human rDNA with 
quantitative Real Time PCR (qRT-PCR) to quantify the transcription activity of yeast 
Pol I in transcribing Human rDNA via initiation of the promoter of Human rDNA.  
The source of the Human rDNA sequence (plus the promoter) was the plasmid of 
pHrP2. It was originally made in the lab of Ingrid Grummt and directly from a generous 
donation from the group of Marikko Laiho at University of John-Hopkins. 
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CHAPTER 2. EXPERIMENT 
2.1 Recombination of Human rDNA and Yeast Integrative Plasmid 
The source of the Human rDNA sequence (plus the promoter) was the plasmid of 
pHrP2, of which the map have been depicted in (Appendix A) and (Appendix C) with 
respective restriction endonucleases to cut. It was originally made in the lab of Ingrid 
Grummt and directly from a generous donation from the group of Marikko Laiho at 
University of John-Hopkins. 
At the beginning there were two vector plasmids as template for accepting the 
insert of human rDNA plus promoter in order to transform the yeast host cells: pRS314-
URA3 and YIPlac211-TG1. Both of these vector plasmids contained URA3 gene. Maps 
of plasmids can be found in the appendix chapter. When the backbone plasmid was 
pRS314-URA3, the two restriction endonucleases to linearize this template as well as to 
cut out the insert of human rDNA plus promoter were BamHI-HF and EcoRI-HF as 
depicted in (Appendix B). When the backbone plasmid was YIPlac211-TG1, the two 
restriction endonucleases were EcoRI-HF and Hind III-HF as depicted in (Appendix D). 
The final selection of the two plasmid to make the recombined plamid for the yeast 
transformation experiment were pHrP2 for the insert and YIPlac211-TG1 for the vector 
template as briefly depicted in (Figure 2.1). As simplified, the loci of cutting by 
restriction endonucleases as well as the sizes of the insert and the linearized template 
were shown in (Figure 2. 1). 
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Figure 2.1 Sizes of Target Fragments, Cutting Loci and Restriction 
Endonucleases for Plasmids 
 
 
The two plasmids, either pHrP2 for insert or YIPlac211-TG1 for template, was 
incubated with restriction endonucleases of HindIII-HF and EcoRI-HF together in NEB 
CutSmart Buffer at 37℃ for 12 hours. Recipes of these two restriction endonuclease 
reactions were depicted in (Table 2. 1) for pHrP2 and (Table 2.2) for YIPlac211-TG1. 
 
Table 2.1  Recipe of Endonuclease Reactions for pHrP2 
Content Volume 
pHrP2 (304.5 ng/L) 7 L 
HindIII-HF (100 Unit/L) 1 L 
EcoRI-HF (100 Unit/L) 2 L 
10  Cut Smart Buffer 1 L 
 
 
Table 2.2  Recipe of Endonuclease Reactions for YIPlac211-TG1 
Content Volume 
YIPlac211-TG1 (150.4 ng/L) 7 L 
HindIII-HF (100 Unit/L) 1 L 
EcoRI-HF (100 Unit/L) 2 L 
10  Cut Smart Buffer 1 L 
 
 
 The following incubations of the resultant reactions had been run at 65 ℃ for 1 
hour. The obtained reaction mixtures were run on agarose gel electrophoresis and the part 
of agarose gel containing the target bands, either the insert of 818 bps and the template of 
3745 base pairs, were cut out under UV light in darkness and the needed DNA segments 
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were collected using Monarch DNA Gel Extraction Kit from NEB (Catalog #: T1020S, 
Lot #: 0041607). 
For this combination of template and insert, the sequence of insert containing 
Human rDNA plus promoter was shown in the Appendix Chapter in (Appendix E). The 
sequence was shown from 5’ terminus to 3’ terminus that contained human rDNA plus 
promoter (underscored) and had the sticky ends in bold alphabets. In the restriction 
endonuclease reactions, the CutSmart buffer from New England Biolab (NEB) was used 
so that the plasmids could be cut by two endonucleases simultaneously. The insert and 
the template were ligated using T4 DNA ligase from NEB. In the ligation reaction, the 
molar ratio of these two segments was controlled to be about HmrDNA: Linearized 
Backbone Plasmid≈6:1. The incubation was done on a thermocycler at 16℃ for 36 hours 
for the insert and template to connect at the sticky ends and at 65℃ for 30 minutes so as 
to inactivate the ligase (Table 2.3). The ligation mixtures containing the recombined 
plasmids containing the human rDNA inserts were used to transform the chemically 
competent E. coli 10β cells from NEB in order to amplify the new recombined plasmid of 
YIPlac211-TG1-HmrDNA. The transformant that had incorporated the recombinant 
plasmid containing YIPlac211-TG1-HmrDNA plasmid was selected using solid agarose 
plate of LB medium with 100mg /L of ampicillin sodium salt from Alfa Aesar (Catalog #: 
J63807; Lot #: M03D004). The survived transformant of E. coli cells in the colonies that 
grew on the solid plate were amplified in liquid YPD medium at 37℃37liquid YPD 
medium overnight. Purified plasmid of YIPlac211-TG1-HmrDNA was extracted and 
purified using a E. Z. N. A. Plasmid DNA Maxi Kit from Omega Bio Tech (Catalog #: 
D6922-00). 
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Table 2.3  Recipe for Inserting Human rDNA into YIPlac211-TG1 
Content Volume 
Human rDNA from pHrP2 (~99..5 ng/L) 12 L 
Linearized YIPlac211-TG1 (~105.4 Unit/L) 2 L 
10  T4 Ligase Buffer 2 L 
T4 Ligase (2,000 Unit/L) 1 L 
DEPC Treated Nuclear Free Water Added to 20 L 
 
2.2  Transformation of Yeast with Plasmid with Human rDNA 
Middle to late log culture of yeast transformant that had an optical density 
between 2 and 4 was centrifuged to remove the liquid medium. The resulting cell pellet 
was washed once with sterile DI water and twice with 100 mM of LiAc-TE-EDTA buffer. 
The resultant yeast cells were finally re-suspended in 2mL of 100 mM LiAc-TE-EDTA 
buffer. Aliquots of 500μL of the suspended cells was added in 2mL micro centrifuge 
tubes. A 50 μL of aliquot of 5 mg/mL salmon sperm DNA (heat denatured at 100℃ for 
10 minutes) and the plasmid DNA (1 to 3 μg in ≤10 μL) were successively added into 
and mixed well with the suspended yeast cells. The reaction mixture was incubated at 
room temperature for 5 minutes and 25 μL of DMSO was added and briefly mixed. After 
an incubation at room temperature for 30 minutes, the reaction mixture was gently mixed 
with 2.0 mL of 40% (v: v) PEG 3350 in 100 mM LiAc-TE-EDTA buffer. The reaction 
mixture was then incubated in a water bath at 30℃ for 30 minutes and heat-shocked at 42℃ 
for 20 minutes. The yeast cells were spun out and added in 2 mL of YPD broth. The 
culture was then incubated at 30℃ with shaking at 250 rpm for 1 hour. This outgrowth 
step is necessary to have sufficient amount of colonies and should always be done. (Once 
it was not done, there could even be risk that no colony generates.) 
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The yeast cells were spun out, washed once with 1mL of sterile DI water and spun 
out again. 1 mL of sterile DI water was added to re-suspend the yeast pellet. All the 
transformation mixture was plated on the –URA3 selective plate to grow the colonies of 
the transformant of the yeast.  
The introduction of Human rDNA into the yeast cells from the YBR140C strain 
was verified using PCR as shown in (Figure 2.2). This operation began with a 
denaturation at 95℃ for 2 minutes followed by a 35-cycle amplification, within which 
each cycle began with a denaturation for 30 seconds at 95℃, followed by an annealing 
for 30 seconds at 60 ℃ and finally a sequence extension for 50 seconds at 72 ℃. These 
amplifying cycles were followed by a 1 round incubation at 72 ℃ for 2 minutes and a 
final standing incubation at 4 ℃. 
 
 
Figure 2.2 PCR Protocol for Detecting Inserted Human rDNA in 
Total DNA Extract from Strain YBR140C-HmrDNA 
2.3 Virtual Screening of NIH/NCATS Library for Possible RNA Pol I Inhibitors 
The yeast RNA Polymerase I crystal structure (PDB access number: 5g5l) solved 
by Engel et al (2016)16 was downloaded from the Protein Data Bank 
(https://www.rcsb.org/structure/5g5l). The file of coordinates for the core enzyme 
structure was obtained using GEDIT by removing the coordinates of the Rrn3 factor. 
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Using this model, amino acid residues on the surface of A43 subunit within a 2 Å 
distance from the surface of Rrn3 in the holozyme complex were selected and highlighted. 
A new Mol2 file was created with the amino acid residues belonging to Rrn3 removed 
using the program of Autodock PMV-1.5.6. This new PDB file was converted into a 
mol2 file using the program of Open Babel GUI. This mol2 file of Yeast RNA Pol I was 
input in the program of SYBYL-X. The biomolecule receptor as the core enzyme part of 
yeast RNA Pol I was initialized by fixing terminal amino acid residues, removing free 
water molecules, protonating the biomolecule receptor’s atoms and building the hydrogen 
bonding, assigning Gasteiger charges to the amino acid residues and minimizing the total 
energy. The multi-channel docking protomol on the structure of Yeast Pol I 5g5l with 
Rrn3 removed was generated. Pick the docking protomol that included most of the amino 
acid residues described above. 
Using Autodock 1. 5. 6, a region for constructing docking protomol was selected 
to include and highlight all of the amino acid residues belonging to the interface between 
RNA Pol I core enzyme and RRN3: PHE138, Ile139, SER141, ALA142, SER143, 
HIS144, LEU148, ASN154, SER156, LYS158, VAL242, ARG1119, ILE1120, 
GLY1121 as depicted in (Figure 2.3). The image on the left shows the RNA Pol I core 
enzyme is in pink and the Rrn3 in green. The three regions in blue are surficial amino 
acids (which are shown in pink in the box in the image on the right) that have direct 
contact with Rrn3 in a complex. A docking box including the protomol was generated 
and depicted in the image on the right side for running the docking of RNA Pol I with 
possible small molecular compounds as inhibitors. The docking region were confined 
within the box that is depicted in the box on the right. The grid center coordinates for this 
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box were x=144.335, y=149.293 and z=99.2 angstroms with numbers of grid points as 
126 in x, 40 in y and 126 in z with an interspace of 0.200 angstroms. 
 
 
Figure 2.3  Docking Protomol for Screening Yeast RNA Pol I Inhibitors 
Using Autodock 
 
 
Multi-channel docking protomols on the structure of yeast Pol I 5g5l were 
generated and a docking protomol was selected to include the same amino acid residues 
as included by the box-shaped docking region in the protomol generated by Autodock 1. 
5. 6. Virtual structures of 500 compounds from the ZINC/NCATS library were converted 
into Mol2 format and input into the program of SYBYL-X. RNA Pol I inhibitor screen 
using SYBYL-X were run using a huge data base including 500 compounds. The docking 
protomol used for SYBYL-X is depicted in (Figure 2.4). Such a protomol included the 
surficial regions of crucial Yeast Pol I subunits in rDNA transcription such as RPA43 and 
RPA190. The compounds were screened with the scores as the negative log values 
reported. The compounds with the top 5 scores in first round of screening and the top 5 
scores in the second round of screening were supposed to be used to run the yeast cellular 
assays to study their dose dependent effects on the growth. The score was the negative 
log values of the binding constants regarding the ligands to the protomols within which 
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they might have contact with the protomol including A43 subunits surface that interacts 
with Rrn3 and disrupts the binding interaction between this subunit and Rrn3 in order to 
inhibit the transcription initiation of RNA Pol I. 
 
 
Figure 2.4  Docking Protomol for Screening Small Compounds from  ZINC/NCATS 
Library of 500 Compounds 
2.4 Yeast Growth Assay with Ligand Compounds 
The following protocol was originally from a published research53 with our 
modification. Individual deletion strains arrayed on YPD/agar were inoculated into 100 
μL of liquid YPD using a 96-head pin tool. Cultures were grown to saturation overnight 
at 30 °C and then stored at 4 °C for 4 hours. The yeast cells were then re-suspended by 
shaking for 15 minutes and each yeast culture’s concentration was normalized by diluting 
to a final OD600 of around 0.02 in a UV fused quartz CV10Q1400S cuvette (Thorlab, 
Newton, NJ) using a Shimadzu UV-1280 Spectrophotometer (Beckman Coulter. Inc. 
Altanta, GA). Normalized cultures were grown in 100-μl volumes in 96-well plates in a 
Tecan GENios microplate reader (MTX Lab Systems, LLC, Bradenton, FL) for 24 h. 
The growth rate of each culture was monitored by measuring the OD570 every 5 min. 
Each ligand compound was test in the growth assays using not only the yeast cells from 
the strain of YBR140C transformant with human rDNA but also the yeast cells from wild 
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type strain of YBR140C that was not transformed. Dose responses of YBR140C-
HmrDNA cells growth were tested against Actinomycin D with a series of concentrations 
of 80μM, 40 μM, 20 μM, 10 μM and 5 μM and against Acebutolol hydrochloride, 
Aripirazole and Cerivastatin Sodium with a series of concentrations of 50μM, 25 μM, 
12.5 μM, 6.25 μM, 3.13 μM and 1.07 μM. The resultant diagrams were plotted using the 
values of CD570 versus the time in minutes. 
2.5 Extraction of Yeast Total RNA 
Two independent colonies of yeast cells of the YBR140C-HmrDNA strain were 
incubated using liquid YPD medium at 240 rpm at 33℃ overnight. 1 mL of YPD 
medium with amplified yeast cells were diluted using fresh liquid YPD medium in a 1: 6 
(v: v) ratio. The diluted yeast cells were then shaken at 240 rpm at 33℃ for 6 hours to 
allow the majority of the amplified cells enter the log phase. For the yeast cells this was 
done to normalize the transcription activity, which was qualitatively tested by firstly 
extracting the total RNA and secondly using reverse transcription to generate the 
corresponding cDNA. 
To extract the total RNA, the cells of the transformed yeast strain YBR140C and 
the wild type YBR140C were both pelleted out into 40μL of final pellets. The pellets 
were respectively suspended in 100 μL of Yeast Suspension Buffer from the Yeast Total 
Protein Extraction Kit (GE Health Care, 28-9444-60AA) with 10 μL of Lifelong 
Zymolyase solutions to lyse the cell walls. The yeast cells were incubate at 37℃ for 1 
hour until most of the them became spheroplasts, which were defined as microbes’ cells 
that had the majority of their cell wall removed and were visibly spherical under 
microscope54 55. The total RNA samples of the yeast spheroplasts were extracted using 
26 
 
the OMEGA E. Z. N. A. Bacterial RNA Kit R6950-01. The operation followed the total 
protocol (file:///D:/Daily%20log%202017-2018/R6950-Bacterial-RNA-Combo-Online-
072817.pdf) except that the spheroplasts were lysed by incubation with 350 μL of BRK 
Lysis Buffer at 4℃ for about 3 hours without vortex with glass beads. The total RNA 
extract samples were denatured using formamide using the following protocol by Masek 
et al (2005) 56. 
2.6 Transcription of Human rDNA in Yeast by Reverse Transcription 
The cDNA of the yeast total RNA was made following the modified typical 
cDNA Synthesis Protocol of Warm Smart RTReverse Transcriptase from New England 
Biolab Inc ( Ipswich, MA). Proper amount of RNA extract sample of yeast was incubated 
with dNTPs mixture at a final concentration of 0.5 mM, Warm Smart RTReverse 
Transcriptase at a final concentration of 7.5 Unit/mL, Random Primer 6 mixture at a final 
concentration of 6 μM, 1 Isothermal Amplification Buffer in each reaction mixture with 
a final volume of 20μL as shown in (Table 2.4). After being mixing by vortexing, all of 
the reaction mixtures were incubate for 20 minutes at 25°C for annealing and 60 minutes 
at 55°C for synthesis. The reactions were quenched by incubation at 80°C for 10 minutes 
in order to inactivate Warm Start RTx Reverse Transcriptase. 
The resultant cDNA was then sampled in a PCR with primers that were designed 
to amplify the human rDNA sequence, the result was visualized using agarose gel 
electrophoresis to check the possible presence of band corresponding to the size close to 
387 base pairs, i. e. the size of the human rDNA. 
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Table 2.4  Recipe for Reverse Transcription of Yeast Total RNA 
Contents Volume 
10  Isothermal Amplification Buffer 2 L 
10 mM dNTP Mixture 1 L 
Random Primers Mixture (62 M)  2 L 
Warm Smart RT  Reverse 
Transcriptase (15,000 Unit/mL) 
0.5 L 
RNA Extract Samples 14.5 L 
 
2.7 Dose Response Test of Human rDNA Transcription to Ligands 
Individual aliquot of yeast transformed cells from the strain of YBR140C-
HmrDNA arrayed on –URA3 agar were inoculated into 100 μL of liquid YPD medium 
using a 8-head pin tool. Cultures were grown to saturation over night at 33°C then stored 
at 4 °C for 4 hrs. The cells were then re-suspended by shaking with a vortex to 
homogenize and the optical density at 600 nm (OD600) of cultures was determined using a 
Shimadzu UV-1280 Spectrophotometer (Beckman Coulter. Inc, Atlanta, GA). Cell 
concentrations were normalized by diluting each culture to a final OD600 of ~0.02. 
Normalized cultures were grown in 100-μl volumes in 96-well plates in Tecan 
GENios microplate readers for 24 h. The growth rate of each culture was monitored by 
measuring the OD570 every 5 min. Dose responses of YBR140C-HmrDNA cells growth 
were tested against Cerivastatin Sodium with concentrations of ~1560 nM, 780 nM and 
390 nM, 195 nM, and 98 nM; (2) Agatroban with concentrations of ~2500 nM, 1250nM; 
Aripirazole with concentrations of ~6250 nM, 3125 nM, 1562 nM, 780 nM. The resultant 
dose response curves were plotted using the values of OD570 versus the time in minutes. 
The general protocol of running qRT-PCR was derived from the protocol 
published by Wang et al (2003)57. The optimal adhesive covers were from Life 
Technologies Holdingsp Pte Ltd, Singapore. The MicroAmp Optical 96-Well Reaction 
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Plates were from Life Technologies Corporation. The PowerUp SYBR Green Master Mix 
(Universal 2 Master Mix for Real-Time PCR Workflows) was from Thermo Fisher 
Scientific. The forward and reverse primers for housekeeping genes-MEP2 and PDC1 
were both from IDT. The primer mixture targeting the amplicon of Yeast rDNA was 
from IDT. 
The housekeeping gene that was selected to run qRT-PCR was MEP2, the gene 
encoding an ammonium permease58. MEP2 gene encodes an ammonium permease with 
higher affinity than the counterpart ammonium permeases encoded by MEP1 and MEP3 
and is necessary for yeast metabolism59. Transcription activities of this enzyme encoding 
gene was used as reference to normalize the transcription activities of target gene, which 
was human rDNA plus promoter.  
The primers for partially amplifying Human rDNA within the transformed Yeast 
YBR14C-HmrDNA were the forward primer: 5’-GGGCCTGCTGTTCTCTCG-3’ and 
the reverse primer: 5’-GAGAACGCCTGACACGCA-3’. The size of corresponding 
amplicon is 197 base pairs with the following sequence in a direction of 5’ to 3’: 
GGGCCTGCTGTTCTCTCGCGCGTCCGAGCGTCCCGACTCCCGGTGCCGGCCCG
GGTCCGGGTCTCTGACCCACCCGGGGGGCGGCGGGGAAGGCGGCGAGGGCC
ACCGTGCCCCCGTGCGCTCTCCGCTGCGGGCGCCCGGGGCGGCCGCGACAAC
CCCACCCCGCTGGCTCCGTGCCGTGCGTGTCAGGCGTTCTC. The housekeeping 
gene that was selected for the RT-PCR was MEP2 gene with the forward primer: 5‘- 
CTGGACATGGTGGTCTAGTT-3’ and the reverse primer: 5’-
GAGGTGACGGAATGTGGT-3’. 
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These two primers were used to amplify part of the MEP2 gene’s sequence that 
could yield amplicons of 100 base pairs with the following sequence of 
CTGGACATGGTGGTCTAGTTTACGCTTTGATACTGGGTAAGCGTAATGACCCT
GTTACACGTAAAGGGATGCCCAAGTACAAACCACATTCCGTCACCTC. 
Samples without template cDNA as the non-template controls (NTC) were set up with 
the same dose of SYBR Green master mix with the identical final volumes as the samples 
with cDNA templates. The recipe of qRT-PCR Reactions for Quantifying Transcription 
Activity of Yeast RNA Pol I is shown in (Table 2.5). The setups for qRT-PCR were 
recorded in Appendices from (Appendix F) to (Appendix L). 
 
Table 2.5  Recipe of qRT-PCR for Transcription Activity of Yeast 
Component Volume (20L/Well) 
PowerUP SYBR Green 
Master Mix (2 ) 
10 L 
Forward and Reverse 
Primers (4 M) 
3 L for each 
 
cDNA and Nuclearase-Free 
Water 
~60 ng, 30 ng, 15 ng, 7.5 ng and 3.8 ng 
for Standard Samples of MEP2 or Human 
rDNA; 
~60 ng for Experimental Samples 
Amplifying Human rDNA 
Total Volume 20 L 
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CHAPTER 3. RESULTS AND DISCUSSIONS 
3.1 Introducing Human rDNA into Yeast Cells 
The first goal of this project was to build a cellular model for studying the 
transcription of human rDNA by yeast RNA Polymerase I. Choosing YIPlac211-TG1 as 
template plasmid was more advantageous because its size was smaller than pRS314-
URA3. Therefore, YIPlac211-TG1introduces less external DNA sequences into the 
genome of yeast host. The other reason for making this choice was because the positions 
of BamHI locus and EcoRI locus within the pRS314-URA3 plasmid was so close (12 
base pairs in between) that it seemed difficult to conduct the restriction endonuclease 
reactions since it took more trials before the insertion was successful. After the first step 
of plasmid construction, the sequencing result showed the yeast integrative plasmid of 
YIPlac211-TG1 had successfully incorporated human rDNA plus the promoter from the 
plasmid of pHrP2 (Figure 3.1).  
Agarose gel electrophoresis of linearized YIPlac211-TG1 plasmid as template and 
human rDNA with promoter as insert. Band 1 in pink box was human rDNA plus 
promoter that was cut out from the pHrP2 plasmid. This insert sequence has the expected 
size of ~818 base pairs. Band 2 and Band 3 in green boxes were the linearized 
YIPlac211-TG1 plasmids with the expected size of ~3745 base pairs. Images from 
electrophoresis depicted resultant DNA segments from restriction endonuclease reactions. 
Comparison with bands from a DNA size marker identified the presence of linearized 
YIPlac211-TG1 plasmid as template as well as an insert composed of human rDNA and 
its promoter from pHrP2 plasmid (Figure 3.1 A). Comparison between wild type and 
linearized reconstructive plasmid built after inserting human rDNA with promoter into 
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the Yeast Integrative plasmid of YIPlac211-TG1. Electrophoresis implicated the size of 
the new plasmid from reaction of DNA ligase and amplification using E. coli 
transformation was the same as the expected size of ~3745 base pairs as shown in Lane 4 
of (Figure 3.1 B). The general process of cutting out human rDNA plus promoter as insert 
and linearizing the template plasmid of Yeast Integrative Plasmid YIPlac211-TG1 that 
contains the same sticky ends as the insert as well as connecting these two parts into a 
new intact plasmid of YIPlac211-TG1-HmrDNAThe whole process of making Yeast 
Integrative Plasmid YIPlac211-TG1-HmrDNA was briefly depicted by (Figure 3.1 C). 
 
 
Figure 3.1 Construction of Yeast Integrative Plasmid Containing Human rDNA plus 
Promoter 
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In the original plan a reporter gene of firefly luciferase was supposed to be 
incorporated in the same plasmid adjacent to the 3’ end of human rDNA in order to 
quantify the transcription activity of yeast RNA Pol I in a high throughput activity assay. 
However, it proved challenging to directly release the reporter luciferase from yeast cell 
possibly due to the impenetrable yeast cell wall, which is resistant to chemical reagents 
like DMSO usually used to break the cell membrane of human cells. Meanwhile, 
degradation of the shield of yeast cell wall requires at least one hour treatment with 
zymolyase. This process might risk degradation of the expressed luciferase. 
Subsequent transformation of YBR140C was done as expected since the 
sequencing data of the total DNA from the transformed yeast cells showed the presence 
of human rDNA sequence within the yeast genome. In the transcription test, the total 
RNA of transformed YBR140C, herein refered to as YBR140C-HmrDNA was reverse-
transcribed. To guard against contamination from genomic DNA, the total RNA was 
treated with DNase. The resultant cDNA was subjected to PCR using primers that can 
amplify certain sequences of human rDNA followed by agarose gel electrophoresis. Both 
the presence of the DNA band with the expected sized after amplification and the 
sequencing result indicated the successful transcription of the human rDNA sequence 
(Appendix M). These results implicated that yeast RNA Pol I could be recruited to the 
promoter region of human rDNA to form the transcription initiation complex as well as 
the elongation complex since the transcription of the incorporated human rDNA had been 
conducted. 
 
 
33 
 
3.2 Identifying the Human rDNA in the Yeast Transformant 
The band size close to 378 base pairs for the PCR of the total DNA extracts of 
YBR140C-HmrDNA Transformant had the close size of the Human rDNA. The result 
implicated the existence of the Human rDNA within the genome of the YBR140C 
transformant with the plasmid of YIPlac211-TG1-HmrDNA. The band with a smaller 
size than 378 base pairs (Figure 3.2) was probably DNA fragments that formed by 
polynucleotide degradation, which was more obvious for the DNA samples obtained 
through crude extraction from yeast cells without scrutinized removal or inactivation of 
cellular Dnase. Lane A shows the result of PCR amplification of total DNA extract of 
Yeast Strain YBR140C-HmrDNA, which was the strain with inserted sequence of 
Human rDNA. Lane B was the  amplified total DNA extract of Yeast Strain YBR140C-
HmrDNA. Lane C was the PCR amplification of pHrP2 Plasmid containing the Human 
rDNA sequence as a positive control.  
 
 
Figure 3.2 Gel Electrophoresis of PCR for Detecting Inserted Human rDNA inYeast 
Strain of YBR140C-HmrDNA 
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Sequence alignment of cDNA from yeast transformant of YBR140C-HmrDNA 
was conducted on the website of Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) with the Human rDNA sequence from the 
sequence map of Plasmid pHrP2. The result (Appendix M) verified the presence of 
Human rDNA within the cDNA from the reverse transcription of total RNA by the 
transcription activity of yeast transformant-YBR140C-HmrDNA. The matching 
percentage between the two sequences that were aligned was 89.3%.  
3.3 Virtual Screening of Ligand-RNA Pol I Interaction 
Molecular docking study using Autodock 1.5.6 showed that CX-5461 might bind 
with the protomol on the interface between RNA Pol I core enzyme and RRN3 tightly 
with a  lowest binding free energy of -5.77 k cal/mol. The structure corresponding with 
such a binding constant was depicted in (Figure 3.3). Molecular docking that followed 
the same protocol showed that Actinomycin D might bind with the protomol also tightly 
since its lowest possible binding free energy was -5.88 k cal/mol. The structure 
corresponding with such a binding constant was depicted in (Figure 3.4).  
 
 
Figure 3.3 Interaction between CX-5461 with Docking Protomol on Yeast RNA Pol I 
Shown by Autodock 
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Figure 3.4 Interaction between Actinomycin D with the Surficial Amino Acids that Had 
Direct Contact with RRN 3 Factor 
 
The same algorithm calculated that cerivastatin sodium had a binding constant of 
-2.62 k cal/mol. In this docking Arg520, Gln553, Lys555, Asn567 and Glu552 were set 
as flexible residues, which were intentionally set up in order to make the docking more 
similar with the real biomolecule within the living yeast cells. The conformation of 
interacting ligand with the RNA Pol I core enzyme was depicted in (Figure 3. 4). 
An ZINC/NCATS small-molecule library of 600 FDA approved compounds were 
used for the virtual screening. The ligands with the high scores for the first round of 
screening were selected with a score higher than 10. These were CX-5461 with a total 
score of 12.0518, Bisoprolol with a total score of 11.4195, Agatroban (NCC-108-04-H04) 
with a total score of 11.3536, Aripirazole with a score of 10.6326, Cerivastatin Sodium 
with a score of 10.3224, Telmisartan with a score of 10.3224 as depicted in (Figure 3.5). 
CX-5461 had already been verified as a strong and selective RNA Pol I inhibitor by prior 
research, a couple of which were briefly recorded in the introduction section. It was 
ranked the top most hit and this result seemed to support that this virtual screening 
strategy could work. Actual dose responses of these screened compounds were still 
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needed for the ultimate evaluation of these compounds as actual “hits” for designing 
anticancer drugs. 
 
 
Figure 3.5 Top Six Hits of First Docking Set of 500 ZINC/NCATS Library Compounds 
with Yeast RNA Pol I 
 
Comparison between the virtual screening result showed that data of CX-5461 
from SYBYL-X, with a docking score of 12.0518 and the binding constant of -5.77 k cal/ 
mol obtained from Autodock were consistent, suggesting that the compound could tightly 
bind with the protomol on RNA Pol I enzyme in contact with Rrn3. Therefore, the result 
complied well with the experimentally observed result from prior publications that CX-
5461 was a strong inhibitor to RNA Pol I. However, the docking score that was 
calculated by SYBYL (10.3224) for Cerivastatin Sodium seemed not to comply well with 
the calculated lowest binding energy as calculated from Autodock 1. 5. 6 (Figure 3.6). 
This calculated lowest binding energy of Cerivastatin Sodium with RPA43 and RPA190 
that interact with Rrn3 was -2.62 k Cal/mol. The possible reason for this inconsistency 
might be because of  different binding affinities between the ligands with the slightly 
different protomols on RNA Pol I. Further verification using yeast cellular transcription 
assays of Cerivastatin Sodium with RNA Pol I was therefore necessary. 
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 Figure 3.6 Interaction between Cerivastatin Sodium at the Interface with RRN3  
 
Another docking was run with a different protomol composed of interspace 
between RPA190 and A34.5 and Rrn3 with the same FDA approved ZINC/NCATS 
Library of 500 compounds were used for the virtual screening following the same 
protocol. The ligands with the high scores for the first round of screening were also 
selected with a score higher than 10. These were carvediol (ZINC01530579) with a total 
score of 10.5365, α-Phylloquinone (ZINC03831330) with a total score of 10.4779, S-
Salmeterol (ZINC03799072) with a total score of 10.2004, R-Salmeterol 
(ZINC03785268) with a total score of 10.1825, Phylloquinone (ZINC12503234) with a 
total score of 10.1099. These results have been summarized in (Figure 3.7).  
 
 
Figure 3.7 Top Five Hits of First Docking Set of Another 500 ZINC Library Compounds 
with Yeast RNA Pol I 
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3.4 Identifying the Human rDNA in the Yeast Transformant 
The growth of yeast cells was quantified by absorbance versus time at a 
wavelength of 570 nm. Comparison of absorbance versus concentrations between both 
wavelengths using samples of yeast cells in liquid YPD media with a series of 
concentrations diluted in folds of 10 (data not shown). Although originally the 
absorbance values against time for yeast cell samples with each compound were set up to 
be for 36 hours, the dynamic ranges were only reported for the portion within 25 
hours/1,500 minutes since this length of time was enough to show the yeast samples’ 
dose responses to the ligands to be tested. 
Dose dependent responses of a couple of ligands had been conducted to assess 
their inhibitory effects on the growth of yeast transformant YBR140C-HmrDNA cells. 
Comparison of the results showed cerivastatin sodium as a stronger inhibitor of growth 
over actinomycin D. Yeast cells were grown with presence of actinomycin D were 
conduc with relatively higher concentrations from 80 M decreasing by two folds to 5 
M (Figure 3.8) and with relatively lower concentrations from 10 M decreasing to 
0.625 M. (Figure 3.9). Growth assays of yeasts were also set up with concentrations of 
cerivastatin sodium from 50 µM decreasing to 1.6 µM by two folds (Figure 3.10) and 
with lower doses of cerivastatin sodium from 1562 nM to 390 µM. (Figure 3.11). 
Remarkably stronger suppression of yeast growth was observed for incubation with 
Cerivastatin Sodium in comparison with the diagram depicting yeast growth with 
presence of Actinomycin D as an established anticancer drug60 and a transcription 
inhibitor61. 
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Figure 3.8 Growth Assay of Yeast YBR140C with pHmrDNA-YIPlac211-TG1 with 
Higher Concentrations of Actinomycin D 
 
 
Figure 3.9 Growth Assay of Yeast YBR140C with pHmrDNA-YIPlac211-TG1 with 
Lower Concentrations of Actinomycin D 
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Figure 3.10 Dose Responses of Yeast Growth to Cerivastatin Sodium at Higher 
Concentrations 
 
 
Figure 3.11 Dose Responses of Yeast Growth to Cerivastatin Sodium at Lower 
Concentrations 
 
Dose response tests of yeast growth to agatroban (Figure 3.12) and aripirazole 
(Figure 3.13) were also shown. Comparison between dose responses implicate that 
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neither of these compounds were remarkable inhibitors to yeast growth as cerivastatin 
sodium.  
 
 
Figure 3.12 Dose Responses of Yeast Growth to Agatroban 
 
 
Figure 3.13 Dose Responses of Yeast Growth to Aripirazole 
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3.5 Dose Response Tests of Human rDNA Transcription by Yeast RNA Pol I 
The yeast cells had been successfully transformed and incorporated human rDNA 
plus promoter and became a new strain of YBR140C-HmrDNA. After the cDNA was 
obtained from the reverse transcription reaction, its transcription activity was tested using 
PCR of which the result indicated Human rDNA within the yeast cells was transcribed. 
Yeast cells that were collected from dose response experiments with a couple of ligands 
and their cDNA were also extracted and used in reactions of PCR at first and qRT-PCR 
to test for the possible inhibitory effects on transcription of RNA Pol I. 
 
3.5.1 Detection of Transcription of Human rDNA in Yeast Transformant 
The size of the target amplicon was 387 base pairs. As depicted in (Figure 3.14), 
the band at the end of Lane (a) shows amplicon of the reference plasmid of pHrP2 as the 
source of human rDNA and promoter. In comparison, amplification reaction of cDNA 
extracts from yeast transformed strain YBR140C-HmrDNA showed bands with very 
similar size as depicted in ends of Lane (b) and Lane (c). The reverse transcription test by 
PCR implicated that the yeast RNA Pol I could transcribe the introduced human rDNA. 
 
 
Figure 3.14 Gel Electrophoresis of Amplified 384 bp Human rDNA in Transformed 
Yeast YBR140C-HmrDNA 
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The assays were conducted using yeast cells from the transformed strain, 
YBR140C-HmrDNA. Based on the successful transcription of human rDNA catalyzed by 
yeast RNA Pol I and the successful reverse transcription, results from PCR amplification 
of the resultant cDNA were likely to implicate dose dependent inhibition of transcription 
activity by agatroban and cerivastatin sodium by (Figure 3.15 a) since the density of the 
target band tended to be increasingly lighter as the dose of ligand decreased. In 
comparison, a dose dependent inhibition by Aripirazole was not observed (Figure 3.15 b). 
These observations needed further quantitative assessment as could be done using qRT-
PCR.  
     
 
Figure 3.15 Dose Effect of Three Ligands to Transcription of Human rDNA in Yeast. a. 
Dose response test using Agatroban and Cerivastatin Sodium and ~45 ng of cDNA from 
YBR140C-HmrDNA. 1: 2500 nM of Agatroban; 2: 1250 nM of Agatroban; 3:1562 nM 
of Cerivastatin Sodium; 4: 781 nM of Cerivastatin Sodium; 5: 390 nM of Cerivastatin 
Sodium; 6: without ligand. b. Dose response test using Aripirazole. 1: 6250 nM of 
Aripirazole; 2: 3125 nM of Aripirazole; 3:1562 nM of Aripirazole; 4: 781 nM of 
Aripirazole; 5: 3125 nM of Aripirazole; 6: without ligand. 
 
 
For both cerivastatin sodium and agatroban the PCR products from the transcribed 
cDNA from the transformed yeast cells of the growth inhibition assay implicated a dose 
dependent inhibition because as the concentration of ligand increased, the shade of the 
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band of the PCR amplicon turned out to be increasingly diminished. The results 
implicated a possible dose dependent inhibitory effect of this compound that might be 
further verified by experiments in qRT-PCR. In comparison, the effect from Aripirazole 
on the transcription of human rDNA by Yeast RNA Pol I was not obvious since the 
densities of the target bands did not show an obvious decreasing tendency as the 
concentration of Aripirazole increased. Data from qRT-PCR could also lend more 
evidence to this result. 
In the dose dependent inhibition test of small compounds using qRT-PCR, an 
alternated algorithm that had ever been described by Livak and Schmittgen (2001)62 was 
used to derive the target Human rDNA’s transcription levels, which were expressed in 2-
ΔΔCT. The CT values obtained from the results of qRT-PCR reactions, the calculated 
values from these CT values and the normalized values of transcription activities were 
recorded in (Table 3.1). CT values for house-keeping gene MEP2 and for target Human 
rDNA were recorded in triplicates of all the three parallel trials that amplifying either 
target human rDNA or internal control gene of MEP2 for yeast cells incubated with a 
certain concentration of ligand or without ligand. The differences between CT values of 
Human rDNA and MEP2 gene were calculated and recorded as ΔCT (HmrDNA- MEP2). 
Their average values were calculated and recorded as ΔCT[Avg, CT (HmrDNA)-
CT(MEP2)] with standard deviations. Each ΔCT [Avg, CT(HmrDNA)-CT(MEP2)] value 
calculated at each concentration of ligand was subtracted by its counterpart ΔCT[Avg, CT 
(HmrDNA)-CT(MEP2)] value measured in reactions without ligand. The results were 
recorded as ΔΔCT [Avg, ΔCT(with ligand)-Avg, ΔCT(no ligand)] plus standard deviations. 
Because of the duplication of DNA during amplification, all of these CT, ΔCT and ΔΔCT 
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values are in logarithm base of 2 and describe the numbers of the amplification cycles of 
DNA. Relative difference in duplication folds required for specific cDNA to reach the 
threshold of detection that are in reverse proportion to concentrations of cDNA can thus 
be calculated using the expression of 2-ΔΔCT [Avg, ΔCT(with ligand)-Avg,ΔCT(no ligand)].  
 
Table 3.1 Summary of Threshold Cycle Values of Threshold Cycles and Normalized 
cDNA Transcription Activities against Different Ligands with Concentrations by 
Duplicated Folds 
 
 
These normalized transcription activity values with standard deviations were 
plotted against three ligands with concentrations increasing with duplicating folds as 
depicted in Figure (Figure 3.16). These reactions showed that both agatroban and 
cerivastatin sodium could inhibit the transcription activity of yeast RNA Pol I by 
measuring   human rDNA levels in a dose-dependent manner. Cerivastatin sodium 
seemed to be a stronger RNA Pol I inhibitor since a decrease by ~46% in transcription 
activity was observed for the yeast Pol I reaction with a ligand concentration of 390 nM. 
At higher duplicated concentrations of 780 nM and 1562 nM the inhibitory effects 
increased as the corresponding transcription activities decreased by ~72% and ~58%. Of 
these the seemingly stronger decrease in transcription activity with a lower ligand 
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concentration was probably due to experimental errors accompanied with the handling of 
decreased yeast cell densities in the liquid medium that could be retrieved in (Figure 
3.16). In comparison Agatroban also reduced activities of RNA Pol I by ~16% and ~65% 
at both concentrations of 2500 nM and 1250 nM. But a lower concentration of 
Cerivastatin Sodium turned out to be a stronger inhibitor of transcription activity of 
Human rDNA than Agatroban in that RNA Pol I activity only had about half of its 
original activity with presence of 390 nM of cerivastatin sodium whereas yeast RNA Pol 
I still had ~84% of activity when the concentration of Agatroban had already reached 
1250 nM, which was 860 nM higher than the concentration of cerivastatin sodium. 
Inhibition of transcription inhibition of Human rDNA by aripirazole still needed 
reproducible results from qRT-PCR experiment. There was an unusual increase of 
normalized transcription activity and standard deviations for compounds treated with 
aripirazole. However, since a relatively low concentration of aripirazole at 780 nM 
caused decrease in transcription activity, this compound might still be a potential 
inhibitor of RNA Pol I’s transcription activity. A more rigorous biological evaluation is 
required. 
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Figure 3.16 Dose Effects of Ligands to Transcription of Human rDNA in Yeast 
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CHAPTER 4. CONCLUSION 
An assay for quantifying transcription activities of RNA Polymerase I has been 
developed. We successfully verified that yeast RNA Pol I could transcribe the 
incorporated human’s rDNA. This observation strongly implicated a transcription 
complex had formed by the transcription factors of our transformed yeast cells. It is 
possible that yeast RNA Pol I was recruited to the human promoter sequence that had 
been incorporated into our yeast cells. More direct data for this recruitment are needed as 
a more compelling evidence. To start with, experiments can be designed to find out 
evidence for DNA-protein interaction between Yeast RNA Pol I and promoter of human 
rDNA using electrophoretic mobility shift assay (EMSA)63. This experiment requires 
both purified RNA Polymerase together with the transcription factors like RRN3, SL1 as 
well as a DNA sequence containing human rDNA promoter. In addition, the experiment 
requires a gel electrophoresis with two comparison groups using the yeast cDNA 
containing sequences of human rDNA plus its promoter region with or without an 
incubation with the yeast cell nuclear extract that contains RNA Pol I. The 
electrophoretic image for the reaction with absence of the band corresponding to the 
amplicons of human rDNA plus the promoter sequence would implicate the binding of 
RNA Pol I because the amplicons of this reaction could not move since they are in 
complex with RNA Pol I.  
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APPENDICES 
 
 
Appendix A Plasmid Maps of pHrP2 that Was Cut by Restriction Endonucleases EcoRI 
and BamHI 
 
 
 
Appendix B Plasmid Map of pRS314-URA3 that Was Cut by Restriction Endonucleases 
EcoRI and BamHI 
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Appendix C Plasmid Maps of pHrP2 that Was Cut by Restriction Endonucleases EcoRI 
and HindIII 
 
 
Appendix D Plasmid Map of YIPlac211-TG-1 that Was Cut by Restriction 
Endonucleases EcoRI and HindIII 
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AAGCTTGGCTGCAGGTCGACGGATCCTTTCTGGCGAGTCCCCGTGCGGA
GTCGGAGAGCGCTCCCTGAGCGCGCGTGCGGCCCGAGAGGTCGCGCCTG
GCCGGCCTTCGGTCCCTCGTGTGTCCCGGTCGTAGGAGGGGCCGGCCGA
AAATGCTTCCGGCTCCCGCTCTGGAGACACGGGCCGGCCCCCTGCGTGT
GGCACGGGCGGCCGGGAGGGCGTCCCCGGCCCGGCGCTGCTCCCGCGT
GTGTCCTGGGGTTGACCAGAGGGCCCCGGGCGCTCCGTGTGTGGCTGCG
ATGGTGGCGTTTTTGGGGACAGGTGTCCGTGTCGCGCGTCGCCTGGGCC
GGCGGCGTGGTCGGTGACGCGACCTCCCGGCCCCGGGGGAGGTATATCT
TTCGCTCCGAGTCGGCATTTTGGGCCGCCGGGTTATTGCTGACACGCTGT
CCTCTGGCGACCTGTCGCTGGAGAGGTTGGGCCTCCGGATGCGCGCGGG
GCTCTGGCCTACCGGTGACCCGGCTAGCCGGCCGCGCTCCTGCTTGAGC
CGCCTGCCGGGGCCCGCGGGCCTGCTGTTCTCTCGCGCGTCCGAGCGTC
CCGACTCCCGGTGCCGGCCCGGGTCCGGGTCTCTGACCCACCCGGGGGG
CGGCGGGGAAGGCGGCGAGGGCCACCGTGCCCCCGTGCGCTCTCCGCTG
CGGGCGCCCGGGGCGGCCGCGACAACCCCACCCCGCTGGCTCCGTGCCG
TGCGTGTCAGGCGTTCTCGTCTCCGCGGGGTTGTCCGCCGCCCCTTCCCC
GGAGTGGGGGGTTGGCCGGAGCCGATCCCCGGGAATTC 
Appendix E Sequence of Insert Containing Human rDNA Plus Promoter that Were 
Integrated within the Yeast Integrative Plasmid of YIPlac211-TG1 
 
 
Appendix F Setup of Non-Template Control Samples for RT-PCR of Dose Response 
Tests of Small Compounds to RNA Pol I with Primers for Human rDNA 
Well 
Number 
Content SYBR Green (2×) Yeast HmrDNA Primer 
Mix_RT-PCR (4µM) 
DEPC 
Water 
1A NTC for HmrDNA 10 µL 3µL 7µL 
1B NTC for HmrDNA 10 µL 3 µL 7 µL 
 
Appendix G Setup of Non-Template Control Samples for RT-PCR of Dose Response 
Tests of Small Compounds to RNA Pol I with Primers for House-Keeping MEP Gene 
Well 
Number 
Content SYBR 
Green (2×) 
MEP2 FWD 
(4µM) 
MEP2 REV 
(4µM) 
DEPC 
Water 
1C NTC for HmrDNA 10 µL 3 µL 3 µL 4 µL 
1D NTC for HmrDNA 10 µL 3 µL 3 µL 4 µL 
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Appendix H Setup of Standard House Keeping MEP2 Gene’s Amplification in qRT-PCR 
with Two-Fold Dilutions from 60 ng/Reaction 
Well 
Number 
Content SYBR 
Green(2) 
MEP2 
FWD 
(4μM) 
MEP2 REV 
(4μM) 
cDNA 
1 E Standard cDNA 1 MEP2 10 μL 3μL 3μL 4 μL of ~15 ng/μL 
1 F Standard cDNA 1 MEP2 10 μL 3μL 3μL 4 μL of ~15 ng/μL 
1 G Standard cDNA 1 MEP2 10 μL 3μL 3μL 4 μL of ~15 ng/μL 
1 H Standard cDNA1/2 MEP2 10 μL 3μL 3μL 4 μL of ~7.5 ng/μL 
2 A Standard cDNA1/2 MEP2 10 μL 3μL 3μL 4 μL of ~7.5 ng/μL 
2 B Standard cDNA1/2 MEP2 10 μL 3μL 3μL 4 μL of ~7.5 ng/μL 
2 C Standard cDNA1/4 MEP2 10 μL 3μL 3μL 4 μL of ~3.8 ng/μL 
2 D Standard cDNA1/4 MEP2 10 μL 3μL 3μL 4 μL of ~3.8 ng/μL 
2 E Standard cDNA1/4 MEP2 10 μL 3μL 3μL 4 μL of ~3.8 ng/μL 
2 F Standard cDNA1/8 MEP2 10 μL 3μL 3μL 4 μL of ~1.9 ng/μL 
2 G Standard cDNA1/8 MEP2 10 μL 3μL 3μL 4 μL of ~1.9 ng/μL 
2 H Standard cDNA1/8 MEP2 10 μL 3μL 3μL 4 μL of ~1.9 ng/μL 
3 A Standard cDNA1/16 MEP2 10 μL 3μL 3μL 4 μL of ~0.95 ng/μL 
3 B Standard cDNA1/16 MEP2 10 μL 3μL 3μL 4 μL of ~0.95 ng/μL 
3 C Standard cDNA1/16 MEP2 10 μL 3μL 3μL 4 μL of ~0.95 ng/μL 
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Appendix I Setup of Standard Human rDNA’s Amplification in qRT-PCR with Two-
Fold Dilutions from 60 ng/Reaction 
Well 
Number 
 
Content 
SYBR 
Green 
(2) 
FWD and REV 
Primer Mix of  
HmrDNA (4μM) 
DEPC 
Water 
(4μM) 
 
cDNA 
 
3 D Standard cDNA 1 HmrDNA 10 μL 3μL 3μL 4 μL of ~15 ng/μL 
3 E Standard cDNA 1 HmrDNA 10 μL 3μL 3μL 4 μL of ~15 ng/μL 
3 F Standard cDNA 1 HmrDNA 10 μL 3μL 3μL 4 μL of ~15 ng/μL 
3 G Standard cDNA1/2 HmrDNA 10 μL 3μL 3μL 4 μL of ~7.5 ng/μL 
3 H Standard cDNA1/2 HmrDNA 10 μL 3μL 3μL 4 μL of ~7.5 ng/μL 
4 A Standard cDNA1/2 HmrDNA 10 μL 3μL 3μL 4 μL of ~7.5 ng/μL 
4 B Standard cDNA1/4 HmrDNA 10 μL 3μL 3μL 4 μL of ~3.8 ng/μL 
4 C Standard cDNA1/4 HmrDNA 10 μL 3μL 3μL 4 μL of ~3.8 ng/μL 
4 D Standard cDNA1/4 HmrDNA 10 μL 3μL 3μL 4 μL of ~3.8 ng/μL 
4 E Standard cDNA1/8 HmrDNA 10 μL 3μL 3μL 4 μL of ~1.9 ng/μL 
4 F Standard cDNA1/8 HmrDNA 10 μL 3μL 3μL 4 μL of ~1.9 ng/μL 
4 G Standard cDNA1/8 HmrDNA 10 μL 3μL 3μL 4 μL of ~1.9 ng/μL 
4 H Standard cDNA1/16 HmrDNA 10 μL 3μL 3μL 4 μL of ~0.95 ng/μL 
5 A Standard cDNA1/16 HmrDNA 10 μL 3μL 3μL 4 μL of ~0.95 ng/μL 
5 B Standard cDNA1/16 HmrDNA 10 μL 3μL 3μL 4 μL of ~0.95 ng/μL 
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Appendix J Setup of Human rDNA’s Dose Response Using qRT-PCR to Ligands of 
Agatroban, Cerivastatin Sodium and Aripirazole  
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Appendix K Setup of House-Keeping MEP2 Gene’s Dose Response to Agatroban, 
Cerivastatin Sodium and Aripirazole in qRT-PCR  
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Appendix L Layout of Samples in a 96 Well Plate for Testing Dose Response of Yeast 
RNA Pol I to Screened Ligands Using RT-PCR 
 
 
Appendix M Sequence Alignment of DNA from YBR140C-HmrDNA 
Strain with Human rDNA Sequence from pHrP2 Plasmid 
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